Imiquimod treatment associated with a reduction in new skin cancer formation

Clinical and Experimental Dermatology

Volumn 34, Issue 1, 2009, Pages 92-

  Czarnecki, C ^a   Czarnecki, D ^a   Carroll, S ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE; IMIQUIMOD;

AGED; ANAMNESIS; ARTICLE; BASAL CELL CARCINOMA; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; HUMAN; LUNG CANCER; MALE; PRIORITY JOURNAL; SKIN CANCER;

ADJUVANTS, IMMUNOLOGIC; AGED; AMINOQUINOLINES; CARCINOMA, BASAL CELL; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; SKIN NEOPLASMS;

EID: 57349118684     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2008.02925.x     Document Type: Article

References (5)

1. Czarnecki D, Sutton T, Czarnecki C, Culjak G. A 10-year prospective study of patients with skin cancer. J Cutan Med Surg 2002 6 : 427 9.
2. Czarnecki C, Czarnecki D. Patients who have had multiple skin cancers develop new skin cancers at a constant rate. Arch Dermatol 2002 138 : 125.
3. Geisse J, Caro I, Lindholm J et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomised, vehicle-controlled studies. J Am Acad Dermatol 2004 50 : 722 33.
4. Schulze HJ, Cribier B, Requena L et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomised vehicle-controlled phase III study in Europe. Br J Dermatol 2005 152 : 939 47.
5. Schiller M, Metze D, Luger TA et al. Immune response modifiers - mode of action. Exp Dermatol 2006 15 : 331 41.